| [1] |
Omaña-Cepeda C,Martínez-Valverde A,Sabater- Recolons M, et al. A literature review and case report of hand, foot and mouth disease in an immunocompetent adult[J]. BMC Res Notes,2016,9(1):165.
|
| [2] |
Kim BI,Ki H,Park S, et al. Effect of climatic factors on hand, foot, and mouth disease in South Korea, 2010-2013[J]. PLoS One,2016,11(6):e0157500.
|
| [3] |
Solomon T,Lewthwaite P,Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis,2010,10(11):778-790.
|
| [4] |
Ping-Chin C,Shou-Chien C,Kow-Tong C. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development[J]. Int J Environ Res Public Health,2016,13(9):890-904.
|
| [5] |
Wang SM,Ho TS,Lin HC, et al. Reemerging of enterovirus 71 in Taiwan: the age impact on disease severity[J]. Eur J Clin Microbiol Infect Dis,2012,31(6):1219-1224.
|
| [6] |
Lee KY. Enterovirus 71 infection and neurological complications[J]. Korean J Pediatr,2016,59(10):395-401.
|
| [7] |
Yang SG,Wu J,Ding C, et al. Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study[J]. Lancet Infect Dis,2017,17(7):716-725.
|
| [8] |
Cox JA,Hiscox JA,Solomon T, et al. Immunopathogenesis and virus-host interactions of enterovirus 71 in patients with hand, foot and mouth disease[J]. Front Microbiol,2017,8(11):2249.
|
| [9] |
Yi EJ,Shin YJ,Kim JH, et al. Enterovirus 71 infection and vaccines[J]. Clin Exp Vaccine Res,2017,6(1):4-14.
|
| [10] |
Tee KK,Lam TT,Chan YF, et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene[J]. J Virol,2010,84(7):3339-3350.
|
| [11] |
Yamayoshi S,Iizuka S,Yamashita T, et al. Human SCARB2-dependent infection by coxsackievirus A7, A14, and A16 and enterovirus 71[J]. J Virol,2012,86(10):5686-5696.
|
| [12] |
Nishimura Y,Lee H,Hafenstein S, et al. Enterovirus 71 binding to PSGL-1 on leukocytes: VP1-145 acts as a molecular switch to control receptor interaction[J]. PLoS Pathog,2013,9(7):e1003511.
|
| [13] |
Ren X,Ma L,Liu QW, et al. The molecule of DC-SIGN captures enterovirus 71 and confers dendritic cell-mediated viral trans-infection[J]. Virol J,2014,11(1):47-53.
|
| [14] |
Yang SL,Chou YT,Wu CN, et al. Annexin Ⅱ binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity[J]. J Virol,2011,85(22):11809-11820.
|
| [15] |
Tan CW,Poh CL,Sam IC, et al. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor[J]. J Virol,2013,87(1):611-620.
|
| [16] |
Yang B,Chuang H,Yang KD. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells[J]. Virol J,2009,6(9):141-146.
|
| [17] |
Kim YI,Song JH,Kwon BE, et al. Pros and cons of VP1-specific maternal IgG for the protection of Enterovirus 71 infection[J]. Vaccine,2015,33(48):6604-6610.
|
| [18] |
Foo DG,Alonso S,Phoon MC, et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides[J]. Virus Res,2007,125(1):61-68.
|
| [19] |
Kim HJ,Son HS,Lee SW, et al. Efficient expression of enterovirus 71 based on virus-like particles vaccine[J]. PLoS One,2019,14(3):e0210477.
|
| [20] |
Zhao H,Li HY,Han JF, et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and Coxsackievirus A16 in mice[J]. Sci Rep,2015,5(1):7878-7885.
|
| [21] |
Ye X,Ku Z,Liu Q, et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms[J]. J Virol,2014,88(1):72-81.
|
| [22] |
Tung WS,Bakar SA,Sekawi Z, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice[J]. Genet Vaccines Ther,2007,5(4):6-18.
|
| [23] |
Chiu CH,Chu C,He CC, et al. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71[J]. Microbes Infect,2006,8(7):1671-1678.
|
| [24] |
Tsou YL,Lin YW,Shao HY, et al. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease[J]. PLoS Negl Trop Dis,2015,9(4):e0003692.
|
| [25] |
Chen HF,Chang MH,Chiang BL, et al. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71[J]. Vaccine,2006,24(15):2944-2951.
|
| [26] |
Arita M,Nagata N,Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys[J]. J Virol,2007,81(17):9386-9395.
|
| [27] |
Meng T,Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice[J]. J Virol,2014,88(10):5803-5815.
|
| [28] |
Zhu FC,Meng FY,Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet,2013,381(9882):2024-2032.
|
| [29] |
Zhu F,Xu W,Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China[J]. N Engl J Med,2014,370(9):818-828.
|
| [30] |
Li R,Liu L,Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children[J]. N Engl J Med,2014,370(9):829-837.
|
| [31] |
Zhang G,Zhou F,Gu B, et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection[J]. Arch Virol,2012,157(4):669-679.
|
| [32] |
Weng TY,Chen LC,Shyu HW, et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells[J]. Antiviral Res,2005,67(1):31-37.
|
| [33] |
Lu G,Qi J,Chen Z, et al. Enterovirus 71 and Coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design[J]. J Virol,2011,85(19):10319-10331.
|
| [34] |
Kishimoto C,Crumpacker CS,Abelmann WH. Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets[J]. J Am Coll Cardiol,1988,12(5):1334-1341.
|
| [35] |
Chen TC,Chang HY,Lin PF, et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71[J]. Antimicrob Agents Chemother,2009,53(7):2740-2747.
|
| [36] |
Arita M,Takebe Y,Wakita T, et al. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection[J]. J Gen Virol,2010,91(Pt 11):2734-2744.
|
| [37] |
Tsai FJ,Lin CW,Lai CC, et al. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins[J]. Food Chem,2011,128(2):312-322.
|
| [38] |
Tan EL,Tan TM,Tak Kwong Chow V, et al. Inhibition of enterovirus 71 in virus-infected mice by RNA interference[J]. Mol Ther,2007,15(11):1931-1938.
|
| [39] |
Ng Q,He F,Kwang J. Recent progress towards novel EV71 anti-therapeutics and vaccines[J]. Viruses,2015,7(12):6441-6457.
|
| [40] |
Kiener TK,Jia Q,Meng T, et al. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein[J]. PLoS Negl Trop Dis,2014,8(5):e2895.
|